Idiopathic pulmonary fibrosis with benign SFTPC variant and pathogenic MARS1 mutations: Can't see the forest for the trees!

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Vincent Cottin reports grants or contracts from Boehringer Ingelheim, outside the submitted work; consulting fees from Astra Zeneca, Boehringer Ingelheim, Celgene / BMS, CSL Behring, Ferrer / United Therapeutics, GSK, Pliant, Pure Tech, RedX, Roche, Sanofi, and Shionogi, outside the submitted work; Fees for lectures and consulting from Boehringer Ingelheim, Ferrer / United Therapeutics, and Roche, outside the submitted work; Support for attending meetings from Boehringer Ingelheim, outside the submitted work; Participation on a data and safety monitoring board for Galapagos, Galecto, and GSK, outside the submitted work; Adjudication committee for Fibrogen, outside the submitted work.

Conflict of interest: Ralph Epaud reports consulting fees from Astra Zeneca, outside the submitted work; Fees for lectures and consulting from Astra Zeneca and GSK, fees for lectures from Chiesi, outside the submitted work; Support for attending meetings from Astra Zeneca and GSK, outside the submitted work.

Conflict of interest: The remaining authors have nothing to disclose.